Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (fatigue) compared with observation alone (low certainty).
1 finding from 1 review
Groin recurrence · patients with Early Vulvar Cancer
Primary Groin Radiotherapy showed no clear difference in groin recurrence compared with primary Groin Surgery (low certainty).
1 finding from 1 review
Disease specific mortality · patients with Early Vulvar Cancer
Primary Groin Radiotherapy showed no clear difference in disease specific mortality compared with primary Groin Surgery (low certainty).
1 finding from 1 review
Overall survival (survival until death from all causes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in overall survival (survival until death from all causes) compared with laparotomy (moderate certainty).
1 finding from 1 review
Recurrence‐free survival · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in recurrence free survival compared with laparotomy (moderate certainty).
1 finding from 1 review
Serious adverse events (range of outcomes) · adult women diagnosed with early stage (I to IIa) endometrial cancer undergoing surgery as primary treatment.
Laparoscopy showed no clear difference in serious adverse events (range of outcomes) compared with laparotomy (low certainty).
1 finding from 1 review
Overall survival (5‐year) · women (18 years and older) diagnosed with stage IB2 cervical cancer
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Progression‐free survival (PSF) · women (18 years and older) diagnosed with stage IB2 cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · women (18 years and older) diagnosed with stage IB2 cervical cancer
It is very uncertain whether chemoradiotherapy changes recurrence compared with radical surgery (very low certainty).
1 finding from 1 review
Adverse events: lymphoedema · women (18 years and older) diagnosed with stage IB2 cervical cancer
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
5‐ year OS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐ year OS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention probably leads to lower 5‐year PFS (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year OS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year OS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
5‐year PFS (stage III) · women with stage III or IV endometrial cancer after primary cytoreductive surgery
The intervention showed no clear difference in 5‐year PFS (stage III) (moderate certainty).
1 finding from 1 review
Intervention not reported
PFS (stage III/IV) Median · women with advanced (stage III/IV) endometrial cancer after surgery and radiotherapy
The intervention showed no clear difference in PFS (stage III/IV) Median (moderate certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after PDS
Small‐volume residual disease (SVRD) < 1 cm probably leads to higher overall survival: Median length of compared with NMRD (moderate certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes overall survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Progression‐free survival · women with advanced EOC after primary IDS
It is very uncertain whether large‐volume residual disease (LVRD) > 1 cm changes progression‐free survival: Median length of compared with small‐volume residual disease (SVRD) < 1 cm (very low certainty).
1 finding from 1 review
Overall survival: Median length of · women with advanced EOC after primary IDS
It is very uncertain whether residual disease (RD) > 0 cm changes overall survival: Median length of compared with NMRD (very low certainty).
1 finding from 1 review